Answers are grounded in this paper and cite their sources.
BACKGROUND: Post-Traumatic Stress Disorder (PTSD) affects approximately 7 % of the United States population and can have significant psychiatric and functional impairments. Repetitive transcranial magnetic stimulation (rTMS) has emerged as a potential treatment, though its efficacy remains inadequately explored. This study evaluates the impact of rTMS on PTSD symptom severity, utilizing the PTSD Checklist for DSM-5 (PCL-5) as a validated outcome measure. METHODS: A retrospective analysis was conducted on 127 patients meeting PTSD criteria (PCL-5 score ≥ 31) who underwent a standardized rTMS protocol between December 2021 and December 2023. Treatment parameters included dorsolateral prefrontal cortex stimulation with individualized motor threshold mapping. PCL-5 scores were assessed pre- and post-treatment using paired t-tests to quantify response to rTMS. RESULTS: The mean pre-treatment PCL-5 score was 49.55, which decreased to 29.07 post-treatment (p < 0.0001). Clinically meaningful response (≥30 % reduction in PCL-5 score) was observed in 65.4 % of patients, with 42.5 % achieving a ≥ 50 % reduction. Female patients demonstrated a greater reduction in PTSD symptom severity compared to males (41.57 % versus 36.64 % reduction). No severe adverse events, including seizures, were reported. CONCLUSIONS: rTMS significantly reduces PTSD symptom severity, with a clinically meaningful response observed in the majority of patients. These findings support the utility of rTMS as an effective, well-tolerated intervention for PTSD. Future studies should investigate long-term symptom stability and optimal stimulation parameters to refine treatment efficacy.
No takes yet. Share an insight, caveat, or question.
Arellano et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: